Collexis Hires Sergio de Farias as Director of Collexis Latin America.

Seasoned Proquest and Elsevier Executive Brings Record of Sales and Marketing Success

COLUMBIA, S.C. -- Collexis Holdings, Inc., (OTCBB: CLXS), a leading developer of high definition search and discovery software, today announced the appointment of Sergio de Farias as Director of Collexis Latin America. In this new position, Farias will oversee the expansion of Collexis into the Latin American Market. Farias comes to Collexis after leading successful efforts as Latin American Sales Director for Proquest and Head of Sales for Latin America for Elsevier Sciences.

"We are thrilled to welcome Sergio to help Collexis handle the demand from our Latin American clients," said Bill Kirkland, Collexis CEO. "Our sophisticated knowledge retrieval and professional networking capabilities will enhance the ability of academics and scientists in the region to locate, distill and manage information to aid in their research and development initiatives."

"The Collexis technology is unique," said Farias. "I am excited about the high definition search concept, which is easily accessible and has the ability to map trends and help researchers generate hypotheses. A helpful tool for any public or private organization that utilizes a considerable amount of digital information, clients in Latin America find it particularly useful because it is largely language independent, allowing for searches in Portuguese/Spanish to be translated to English."

Farias holds a degree in Architecture and Urbanism from Bennett University in Rio de Janeiro and has completed post-graduate work in Administrative and Civil Rights at Fundacao Getulio Vargas in Rio de Janeiro.

About Collexis Holdings, Inc.

Named a Trend-Setting product of 2007 by KMWorld, Collexis Holdings, Inc., a leading developer of high definition search and discovery software since 1999, is headquartered in Columbia, South Carolina (USA), with three subsidiaries: Collexis Inc. in Columbia, South Carolina, USA; Collexis, B.V. in Geldermalsen, The Netherlands; and SyynX Solutions GmBH in Cologne, Germany. Collexis proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis's current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; University of California, San Francisco; University of South Carolina; Erasmus University Library; Merck & Co.; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. For more information, please visit www.collexis.com.

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the acquisition of SyynX; with whether the benefits of the SynnX acquisition will occur as anticipated, with the planned launch of the company's social networking and collaboration platform for the biomedical research community; and with whether the company will in fact be able to make additional strategic acquisitions. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-KSB for the period ended June 30, 2007. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.